David P. L. B.
- Country
- Spain
- Department
- Department of oncology
Research Overview
- Phase 1 Dose Escalation and Cohort Expansion Study of Anti-PD-1 Monoclonal Antibody TSR-042 in Advanced Solid Tumors
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Phase 1/2 Study of EIK1005 Monotherapy and EIK1005 Plus Pembrolizumab in Patients With Advanced Solid Tumors
Data & Insights
Has run more than one trial at 129 of 326 partner sites.
Specializations
Colorectal Cancer Research
This investigator specializes in advanced therapeutic approaches for metastatic colorectal cancer, with particular focus on novel treatment combinations and targeted therapies.
- BRAF and RAS mutation studies
- Anti-EGFR therapy evaluation
- Immunotherapy applications
The research encompasses both early-stage and advanced disease management, including specific focus on dMMR/MSI-H colon cancer variants.
Targeted Therapy Innovation
Expertise in developing and evaluating combination treatment strategies, particularly involving targeted agents and immunotherapeutic approaches.
- Novel drug combinations
- Molecular targeting strategies
- Resistance mechanism studies
Special interest in biomarker-driven treatment approaches and personalized medicine protocols.
Advanced Solid Tumors
Conducts research on various types of advanced solid tumors, including specialized work in squamous cell carcinoma and other gastrointestinal malignancies.
- Pharmacokinetic studies
- Treatment optimization
- Clinical response assessment
Focus on developing innovative therapeutic strategies for treatment-resistant cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.